The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice
Open accessAbstract
Rationale: Atheroprogression is a consequence of nonresolved inflammation, and currently a comprehensive overview of the mechanisms preventing resolution is missing. However, in acute inflammation, resolution is known to be orchestrated by a switch from inflammatory to resolving lipid mediators. Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression. Objective: To understand the lipid mediator balance during atheroprogression and to establish an interventional strategy based on the delivery of resolving lipid mediators. Methods and Results: Aortic lipid mediator profiling of aortas from Apoe −/− mice fed a high-fat diet for 4 weeks, 8 weeks, or 4 months revealed an expansion of inflammatory lipid mediators, Leukotriene B4 and Prostaglandin E2, and a concomitant decrease of resolving lipid mediators, Resolvin D2 (RvD2) and Maresin 1 (MaR1), during advanced atherosclerosis. Functionally, aortic Leukotriene B4 and Prostaglandin E2 levels correlated with traits of plaque instability, whereas RvD2 and MaR1 levels correlated with the signs of plaque stability. In a therapeutic context, repetitive RvD2 and MaR1 delivery prevented atheroprogression as characterized by halted expansion of the necrotic core and accumulation of macrophages along with increased fibrous cap thickness and smooth muscle cell numbers. Mechanistically, RvD2 and MaR1 induced a shift in macrophage profile toward a reparative phenotype, which secondarily stimulated collagen synthesis in smooth muscle cells. Conclusions: We present evidence for the imbalance between inflammatory and resolving lipid mediators during atheroprogression. Delivery of RvD2 and MaR1 successfully prevented atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative strategy to resolve arterial inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As summarized in this Review, treatment of Western-diet-fed Ldlr−/− mice with athero-targeted nanoparticles packaged with a pro-resolving peptide derived from annexin A1 (Ac2–26) or with SPMs markedly suppressed the formation of necrotic, thin-capped plaques36,38,99,109,118.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“in mice, the advanced atherosclerotic lesions are deficient in pro-resolving lipid mediators37,38.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B. O., Dahlén, S., LINDGREN, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Nathan, C., & Ding, A. (2010) · Cell · doi:10.1016/j.cell.2010.02.029 · Cited by 2,183
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453
Inducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville‐Nash, P., Willis, D., Chivers, J. E., Paul‐Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
Resolvin E1 and protectin D1 activate inflammation-resolution programmes
Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007) · Nature · doi:10.1038/nature05877 · Cited by 1,219
Macrophage death and defective inflammation resolution in atherosclerosis
Tabas, I. (2010) · Nature Reviews Immunology · doi:10.1038/nri2675 · Cited by 1,120
Novel Markers to Delineate Murine M1 and M2 Macrophages
Jablonski, K. A., Amici, S. A., Webb, L. M., Ruiz-Rosado, J. D. D., Popovich, P. G., Partida-Sanchez, S., & Guerau-de-Arellano, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145342 · Cited by 978
Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo
Lämmermann, T., Afonso, P. V., Angermann, B., Wang, J. M., Kastenmüller, W., Parent, C. A., & Germain, R. N. (2013) · Nature · doi:10.1038/nature12175 · Cited by 939
Cited by
Sorted by citations
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,085
Self-citationMonocyte-macrophages and T cells in atherosclerosis
Tabas, I., & Lichtman, A. H. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.008 · Cited by 646
Neutrophils as protagonists and targets in chronic inflammation
Soehnlein, O., Steffens, S., Hidalgo, A., & Weber, C. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.10 · Cited by 623
Self-citationSerhan, C. N. (2017) · The FASEB Journal · doi:10.1096/fj.201601222r · Cited by 566
Bioactive Lipids and Chronic Inflammation: Managing the Fire Within
Chiurchiù, V., Leuti, A., & Maccarrone, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00038 · Cited by 427
Inflammation during the life cycle of the atherosclerotic plaque
Libby, P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab303 · Cited by 453
An, Y., Zhang, H., Wang, C., Jiao, F., Xu, H., Wang, X., Luan, W., Ma, F., Ni, L., Tang, X., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802805rr · Cited by 414
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 376
Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis
Yurdagul, A., Doran, A. C., Cai, B., Fredman, G., & Tabas, I. A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00086 · Cited by 300
Coronary Atherosclerotic Vulnerable Plaque: Current Perspectives
Stefanadis, C., Antoniou, C. K., Tsiachris, D., & Pietri, P. G. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005543 · Cited by 289
Dobrev, D., Heijman, J., Hiram, R., Li, N., & Nattel, S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00759-w · Cited by 284
The role of non-resolving inflammation in atherosclerosis
Kasikara, C., Doran, A. C., Cai, B., & Tabas, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97950 · Cited by 266
MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis
Cai, B., Thorp, E. B., Doran, A. C., Sansbury, B. E., Daemen, M. J. A. P., Dorweiler, B., Spite, M., Fredman, G., & Tabas, I. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90520 · Cited by 262
New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration
Serhan, C. N., Chiang, N., & Dalli, J. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.08.002 · Cited by 253
Macrophage Death as a Pharmacological Target in Atherosclerosis
Martinet, W., Coornaert, I., Puylaert, P., & Meyer, G. R. Y. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00306 · Cited by 232
Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis
Moore, K. J., Koplev, S., Fisher, E. A. A., Tabas, I. A., Björkegren, J., Doran, A. C., & Kovacic, J. C. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.2147 · Cited by 229
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets
Meyer, G. R. Y. D., Zurek, M., Puylaert, P., & Martinet, W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00957-0 · Cited by 221
Boosting Inflammation Resolution in Atherosclerosis
Fredman, G., & Tabas, I. A. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.018 · Cited by 179
Inflammation Resolution: Implications for Atherosclerosis
Doran, A. C. (2022) · Circulation Research · doi:10.1161/circresaha.121.319822 · Cited by 181
Macrophages in vascular inflammation and atherosclerosis
Cochain, C., & Zernecke, A. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-1941-y · Cited by 168
Fredman, G., & Serhan, C. N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00984-x · Cited by 176
The walking dead: macrophage inflammation and death in atherosclerosis
Kavurma, M. M., Rayner, K. J., & Karunakaran, D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000394 · Cited by 146
Dalli, J., & Serhan, C. N. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14336 · Cited by 138
Harwood, J. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108838 · Cited by 147
Crosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability
Yurdagul, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316233 · Cited by 138
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt, S. C. R., Libby, P., Budoff, M. J., Bhatt, D. L., & Mason, R. P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01075-x · Cited by 156
Resolvin D1 promotes the targeting and clearance of necroptotic cells
Gerlach, B. D., Marinello, M., Heinz, J., Rymut, N., Sansbury, B. E., Riley, C. O., Sadhu, S., Hosseini, Z., Kojima, Y., Tang, D. D., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0370-1 · Cited by 129
Doran, A. C., Özcan, L., Cai, B., Zheng, Z., Fredman, G., Rymond, C. C., Dorweiler, B., Sluimer, J. C., Hsieh, J., Kuriakose, G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94735 · Cited by 113
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Shibabaw, T. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03965-7 · Cited by 108
Specialized pro-resolving mediators in cardiovascular diseases
Fredman, G., & Spite, M. R. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.02.003 · Cited by 103
2016 Russell Ross Memorial Lecture in Vascular Biology
Tabas, I. A. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308036 · Cited by 92
Targeting immune cell recruitment in atherosclerosis
Döring, Y., van der Vorst, E. P. C., & Weber, C. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01023-z · Cited by 99
Self-citationTang, S. J., Wan, M., Huang, W. G., Stanton, R. C., & Xu, Y. (2018) · Mediators of Inflammation · doi:10.1155/2018/2380319 · Cited by 90
Carracedo, M., Artiach, G., Arnardottir, H. H., & Bäck, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00767-y · Cited by 100
Rinne, P., Guillamat‐Prats, R., Rami, M., Bîndilă, L., Ring, L., Lyytikäinen, L., Raitoharju, E., Oksala, N., Lehtimäki, T. J., Weber, C., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311185 · Cited by 88
Self-citationPro-resolving lipid mediators in vascular disease
Conte, M. S., Desai, T. A., Wu, B., Schaller, M. S., & Werlin, E. C. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97947 · Cited by 82
The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection
Arnardottir, H., Thul, S., Pawelzik, S., Karadimou, G., Artiach, G., Gallina, A. L., Mysdotter, V., Carracedo, M., Tarnawski, L., Caravaca, A. S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142883 · Cited by 87
Resolvin D2 Restrains Th1 Immunity and Prevents Alveolar Bone Loss in Murine Periodontitis
Mizraji, G., Heyman, O., Dyke, T. E. V., & Wilensky, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00785 · Cited by 81
Hosseini, Z., Marinello, M., Decker, C., Sansbury, B. E., Sadhu, S., Gerlach, B. D., Ramos, R. B., Adam, A. P., Spite, M. R., & Fredman, G. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315758 · Cited by 81
Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy
Dort, J., Orfi, Z., Fabre, P., Molina, T., Conte, T. C., Greffard, K., Pellerito, O., Bilodeau, J., & Dumont, N. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26516-0 · Cited by 81
Sun, S., Wang, J., Wang, J., Wang, F., Yao, S., & Xia, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01323 · Cited by 78
Maresin-1 and Inflammatory Disease
Saito‐Sasaki, N., Sawada, Y., & Nakamura, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031367 · Cited by 78
Macrophage Responses to Environmental Stimuli During Homeostasis and Disease
Rasheed, A., & Rayner, K. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab004 · Cited by 83
Maresin 1 Promotes Wound Healing and Socket Bone Regeneration for Alveolar Ridge Preservation
Wang, C., Yu, S. H., Fretwurst, T., Larsson, L., Sugai, J. V., Oh, J., Lehner, K. A., Jin, Q., & Giannobile, W. V. (2020) · Journal of Dental Research · doi:10.1177/0022034520917903 · Cited by 69
Rayner, K. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309229 · Cited by 68
Do patients benefit from omega-3 fatty acids?
Sherratt, S. C. R., Mason, R. P., Libby, P., Steg, P. G., & Bhatt, D. L. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad188 · Cited by 75
Macrophage fatty acid metabolism and atherosclerosis: The rise of PUFAs
Ménégaut, L., Jalil, A., Thomas, C., & Masson, D. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.002 · Cited by 64
Chattopadhyay, R., Raghavan, S., & Rao, G. N. (2017) · Redox Biology · doi:10.1016/j.redox.2017.02.023 · Cited by 64
Wu, B., Mottola, G., Schaller, M. S., Upchurch, G. R., & Conte, M. S. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.07.005 · Cited by 66
Zhang, Y., Li, J.-S., Zhao, J., Li, X., Wang, Z., Huang, Y., Zhang, H., Liu, Q., Lei, Y., & Ding, D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202313890 · Cited by 64
Involvement of Inflammation and Its Resolution in Disease and Therapeutics
Alfaro, S., Acuña, V., Ceriani, R., Cavieres, M. F., Oppenheimer, C. W., & Campos‐Estrada, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810719 · Cited by 68
Welty, F. K., Schulte, F., Alfaddagh, A., Elajami, T. K., Bistrian, B. R., & Hardt, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002471r · Cited by 58
Seneviratne, A. N., Cave, L., Hyde, G. D., Moestrup, S. K., Carling, D., Mason, J. C., Haskard, D. O., & Boyle, J. J. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa171 · Cited by 57
Tang, S. J., Gao, C., Long, Y., Huang, W. G., Chen, J., Fan, F., Jiang, C., & Xu, Y. (2017) · Mediators of Inflammation · doi:10.1155/2017/2438247 · Cited by 56
Bioactive Lipid Signaling in Cardiovascular Disease, Development, and Regeneration
Wasserman, A. H., Venkatesan, M., & Aguirre, A. (2020) · Cells · doi:10.3390/cells9061391 · Cited by 50
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect
Fredman, G., & MacNamara, K. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab309 · Cited by 55
Potential Clinical Applications of Pro-Resolving Lipids Mediators from Docosahexaenoic Acid
Beyer, M. P., Videla, L. A., Farías, C., & Valenzuela, R. (2023) · Nutrients · doi:10.3390/nu15153317 · Cited by 54
Darwesh, A. M., Sosnowski, D. K., Lee, T. Y., Keshavarz-Bahaghighat, H., & Seubert, J. M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.037 · Cited by 51
Tułowiecka, N., Kotlęga, D., Prowans, P., & Szczuko, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207628 · Cited by 45
Impact of Age, Menopause, and Obesity on Oxylipins Linked to Vascular Health
Pauls, S. D., Du, Y., Clair, L., Winter, T., Aukema, H. M., Taylor, C. G., & Zahradka, P. C. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315133 · Cited by 45
Effect of ω-3 Polyunsaturated Fatty Acids-Derived Bioactive Lipids on Metabolic Disorders
Duan, J., Song, Y., Zhang, X., & Wang, C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.646491 · Cited by 47
Suzumura, A., Terao, R., & Kaneko, H. (2020) · Antioxidants · doi:10.3390/antiox9100920 · Cited by 44
Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension
del Campo, L. S. D., García‐Redondo, A. B., Rodrı́guez, C., Zaragoza, C., Duro‐Sánchez, S., Palmas, F., de Benito-Bueno, Á., Socuéllamos, P. G., Peraza, D. A., Rodrigues‐Díez, R., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19448 · Cited by 45
Yang, Y., Zhu, Y., Xiao, J., Tian, Y., Ma, M., Li, X., Li, L., Zhang, P., Li, M., Wang, J., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114005 · Cited by 44
Schaller, M. S., Chen, M., Colas, R. A., Sorrentino, T. A., Lazar, A., Grenon, S. M., Dalli, J., & Conte, M. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016113 · Cited by 46
Bardin, M., Pawelzik, S., Lagrange, J., Mahdi, A., Arnardottir, H. H., Regnault, V., Fève, B., Lacolley, P. J., Michel, J., Mercier, N., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115075 · Cited by 43
Resolvins as proresolving inflammatory mediators in cardiovascular disease
Capó, X., Martorell, M., Busquets-Cortés, C., Tejada, S., Tur, J. A., Pons, A., & Sureda, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.018 · Cited by 46
Calderin, E. P., Zheng, J., Boyd, N. L., McNally, L. A., Audam, T. N., Lorkiewicz, P., Hill, B. G., & Hellmann, J. L. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101637 · Cited by 41
Roles of Resolvins in Chronic Inflammatory Response
Liu, C., Fan, D., Lei, Q., Lü, A., & He, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314883 · Cited by 42
van der Vorst, E. P. C., Mandl, M., Müller, M., Neideck, C., Jansen, Y. J. F. M., Hristov, M., Gencer, S., Peters, L. J. F., Meiler, S. U., Feld, M., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312386 · Cited by 41
Self-citationSato, T., Horikawa, M., Takei, S., Yamazaki, F., Ito, T. K., Kondo, T., Sakurai, T., Kahyo, T., Ikegami, K., Sato, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313093 · Cited by 41
Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy
Kim, A. S., & Conte, M. S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.011 · Cited by 42
Dhawan, U. K., Singhal, A., & Subramanian, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105699 · Cited by 41
Han, Y., KyeongJin, L., Saha, A., Han, J., Choi, H., Noh, M., Lee, Y., & Lee, M. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.094 · Cited by 43
Unified nexus of macrophages and maresins in cardiac reparative mechanisms
Jadapalli, J. K., & Halade, G. V. (2018) · The FASEB Journal · doi:10.1096/fj.201800254r · Cited by 39
Liu, W., Yang, Y.-H., Wang, Y.-C., Chang, W., & Wang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311012 · Cited by 40
Acute coronary syndrome and acute kidney injury: role of inflammation in worsening renal function
Ortega-Hernandez, J. A., Springall, R., Sánchez‐Muñoz, F., Arana-Martinez, J.-C., González‐Pacheco, H., & Bojalil, R. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0640-0 · Cited by 38
Atherothrombosis and the NLRP3 inflammasome – endogenous mechanisms of inhibition
Satish, M., & Agrawal, D. K. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.003 · Cited by 39
The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies
Giardini, E., Moore, D., Sadlier, D. M., Godson, C., & Brennan, E. P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118615 · Cited by 41
Qiao, N., Lin, Y., Wang, Z., Chen, J., Ge, Y.-Y., Yao, S., & Gong, J. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2020.06.062 · Cited by 38
Maresin 1 attenuates pro-inflammatory reactions and ER stress in HUVECs via PPARα-mediated pathway
Jung, T. W., Park, H. S., Choi, G. H., Kim, D., Ahn, S. H., Kim, D.-S., Lee, T., & Jeong, J. H. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3392-y · Cited by 35
Zheng, J., Calderin, E. P., Hill, B. G., Bhatnagar, A., & Hellmann, J. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900144 · Cited by 33
Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling
del Campo, L. S. D., Rodrigues‐Díez, R., Salaíces, M., Briones, A. M., & García‐Redondo, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073592 · Cited by 36
Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis
Zahoor, I., & Giri, S. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08796-4 · Cited by 37
Miao, Z., Schultzberg, M., Wang, X., & Zhao, Y. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.12.037 · Cited by 34
Inflammation and Resolution in Obesity-Related Cardiovascular Disease
Karakasis, P., Stachteas, P., Iliakis, P., Sidiropoulos, G., Grigoriou, K., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010535 · Cited by 32
Inflammatory Basis of Atherosclerosis: Modulation by Sex Hormones
Nasser, S. A., Afify, E. A., Kobeissy, F. H., Hamam, B., Eid, A. H., & El‐Mas, M. M. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210122142811 · Cited by 32
Kumrić, M., Borovac, J. A., Martinović, D., Kurir, T. T., & Božić, J. (2021) · Biomolecules · doi:10.3390/biom11060881 · Cited by 32
Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis
Lubrano, V., Ndreu, R., & Balzan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021637 · Cited by 33
The diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 31
Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases
Shang, P., Zhang, Y., Ma, D., Hao, Y., Wang, X., Xin, M., Zhang, Y., Zhu, M., & Feng, J. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1691525 · Cited by 30
Sokal, D. M., McSloy, A., Donegà, M., Kirk, J., Colas, R. A., Doležalová, N., Gómez, E. A., Gupta, I., Fjordbakk, C. T., Ouchouche, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649786 · Cited by 30
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis
van der Vorst, E. P. C., Peters, L. J. F., Müller, M., Gencer, S., Yan, Y., Weber, C., & Döring, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00531 · Cited by 29
Self-citationKraft, J. D., Blomgran, R., Bergström, I., Soták, M., Clark, M., Rani, A., Rajan, M. R., Dalli, J., Nyström, S., Quiding‐Järbrink, M., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202101219rr · Cited by 29
Polyunsaturated Fatty Acids and Atherosclerosis: Insights from Pre‐Clinical Studies
Ramji, D. P. (2018) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201800029 · Cited by 28
Artru, F., McPhail, M. J. W., Triantafyllou, E., & Trovato, F. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867261 · Cited by 29
Molecular Pharmacology of Inflammation Resolution in Atherosclerosis
Kotlyarov, S. N., & Котлярова, А. А. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094808 · Cited by 31
Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?
Bhattacharya, P., Kanagasooriyan, R., & Subramanian, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102283 · Cited by 31
Metadata
- Authors
- Viola, J. R., Lemnitzer, P., Jansen, Y., Csaba, G., Winter, C., Neideck, C., Silvestre-Roig, C., Dittmar, G., Döring, Y., Drechsler, M., Weber, C., Zimmer, R., Cenac, N., & Soehnlein, O.
- Affiliations
- Inserm (FR)
- From the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin...
- ORCID
- Venue
- Circulation Research
- Published
- 2016-10-14
- Volume
- 119
- Issue
- 9
- Pages
- 1030-1038
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2510102221
- Cited by
- 226
- References
- 55
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 24 · 2023: 26 · 2022: 33 · 2021: 26 · 2020: 22 · 2019: 24 · 2018: 19 · 2017: 22 · 2016: 3
- FWCI
- 23.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Agence Nationale de la Recherche
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- maresin 1, resolvin D2, inflammation resolution, lipid mediators, atherosclerosis, plaque stability, leukotriene B4, prostaglandin E2, macrophage polarization, smooth muscle cells, collagen synthesis, high-fat diet, necrotic core
- MeSH terms
- Animals, Cells, Cultured, Docosahexaenoic Acids, Mice, Inbred C57BL, Drug Delivery Systems, Mice, Knockout, Disease Progression, Inflammation Mediators, Atherosclerosis, Lipid Metabolism, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
